General anesthetics bind tubulin and alter the electronic and optical behavior of microtubules.

Two independent lines support the claim as worded: measured anesthetic reduction of microtubule exciton diffusion, and independent photolabeling of β-tubulin with functional consequences in vivo. Held at provisional by the modest effect size, two agents only, and the absence of any specificity panel — the picrotoxin result means this may be general pharmacological perturbability rather than anesthesia-specific.

Experimental evidence directly links general anesthetics (etomidate, isoflurane, and a research anthracene) to altered microtubule exciton diffusion and localized tubulin binding. The support is provisional because the optical effect was modest (~13%) and currently lacks independent replication. Critically, the assay lacks specificity, as a convulsant (picrotoxin) produced a comparable effect.

Kalra’s experiment directly demonstrates that etomidate and isoflurane reduce a specific microtubule exciton-diffusion length, clearly showing anesthetics alter microtubule optical behavior. Emerson’s photolabeling of β-tubulin by 1-aminoanthracene, along with microtubule-stabilizer protection of tadpoles, independently shows direct anesthetic binding to tubulin with functional consequences. Proteomic work also identifies tubulin among many anesthetic-binding proteins. However, the Kalra effect is modest, unreplicated, and compromised in specificity by the similar effect of picrotoxin; and the anthracene anesthetic is a non-clinical compound. Thus binding and perturbation are fairly well supported, but their generality and anesthetic-specificity remain to be established. The major objection is that without a systematic potency series including nonimmobilizers and hydrophobic controls, the observed effects may reflect generic perturbability, not anesthetic mechanism.

Two independent experimental lines support the statement as worded. Kalra et al. measured etomidate and isoflurane reducing microtubule excitation diffusion length; Emerson et al., from a laboratory with no Orch OR commitment, identified β-tubulin as the photolabeled target of an anthracene anesthetic, mapped binding near the colchicine site, and showed microtubule stabilizers shifting a behavioral endpoint. Held to provisionally by a single unreplicated optical experiment, a research rather than clinical anesthetic in Emerson, a modest ~13% diffusion-length effect, and the picrotoxin comparison inside Kalra showing a convulsant affecting the same assay. The strongest opposing consideration is that specificity: if small hydrophobic molecules of opposite pharmacology all perturb the photophysics, the observation licenses further work without selecting an anesthetic mechanism.

Two independent experimental lines support the claim as worded: Kalra et al. directly observed etomidate and isoflurane reducing microtubule excitation diffusion, and Emerson et al. — an anesthesia laboratory with no Orch OR commitment — identified β-tubulin as the photolabeled target of an anthracene anesthetic with functional behavioral consequences in tadpoles. Proteomic photolabeling places tubulin among many anesthetic-binding brain proteins. The strongest opposing consideration comes from inside the flagship experiment itself: picrotoxin, a convulsant, affected the same assay comparably, so what is measured may be general perturbability of microtubule photophysics by hydrophobic molecules rather than anything anesthesia-specific. The modest effect size, two-agent scope, research-compound caveat, and absent potency series hold the grade at provisional.

Two partly independent experimental lines support the statement as worded. Kalra et al. measured etomidate and isoflurane reducing microtubule excitation diffusion length, and Emerson et al. — an anesthesia-mechanisms laboratory with no Orch OR commitment — photolabeled β-tubulin, mapped binding near the colchicine site, and showed stabilizers shifting the concentration needed for a behavioral effect. The binding half of the claim is the better evidenced; the "alters electronic and optical behavior" half rests on a single unreplicated experiment with two agents, a ~13% effect, and the theory's authors among the co-authors. The strongest opposing consideration is specificity, and it comes from inside the flagship experiment rather than from critics: picrotoxin, a convulsant, perturbed the same assay comparably, which is what one expects if the assay measures perturbability of microtubule photophysics by small hydrophobic molecules generally. That does not undercut the claim as worded, which makes no specificity assertion, but it caps how far the claim can be carried.

Two partly independent lines support the claim as worded — the exciton-diffusion reduction (ORCH-E002) and β-tubulin photolabeling with functional consequences (ORCH-E009). Held at provisional by modest effect size, only two clinical agents, and the missing specificity panel implied by ORCH-E003.

Two partly independent lines still support the claim as worded — ORCH-E002 and the photolabeling result in ORCH-E009 — held at provisional by modest effect size, two agents, and the missing specificity panel implied by ORCH-E003.

Two partly independent lines support the claim as worded — ORCH-E002 and the photolabeling and polymerization results in ORCH-E009 — held at provisional by modest effect size, few agents, and the missing specificity panel implied by ORCH-E003.

Independent experiments support the endpoints of this mechanistic claim: anesthetics like etomidate and isoflurane reduce microtubule exciton diffusion length, and the anesthetic 1-aminoanthracene photolabels β-tubulin. However, the effect size in the optical assay is modest, and crucially, the convulsant picrotoxin produced a comparable effect. This severely questions whether this perturbation is specific to anesthetics or just a general response to small hydrophobic molecules.

Kalra’s spectroscopy shows that etomidate and isoflurane reduce exciton-diffusion length in polymerized microtubules, directly demonstrating alteration of microtubule optical behavior by clinical anesthetics. Emerson et al. independently identify β-tubulin as a photolabeled target of an anthracene anesthetic and show microtubule stabilizers shift anesthetic immobilization thresholds in tadpoles. The main counterpoint is specificity: the same Kalra assay responds comparably to picrotoxin, a convulsant, indicating the observable may simply reflect generic perturbation by small hydrophobic molecules, and only two anesthetics have been tested so far.

Two independent experimental lines support the claim as worded: Kalra et al. observed etomidate and isoflurane reducing microtubule excitation diffusion, and Emerson et al., from a laboratory with no Orch OR commitment, photolabeled β-tubulin with an anthracene anesthetic and found microtubule stabilizers shifting a behavioral endpoint. The claim does not assert specificity, coherence, or a consciousness role, so those absences do not subtract from it. The strongest opposing consideration is internal to Kalra: picrotoxin, a convulsant, affected the same assay, which does not deny that anesthetics bind and perturb microtubules but shows the perturbation may be generic hydrophobic pharmacology rather than an anesthesia-specific interaction.

Two independent experimental lines support the claim as worded: Kalra et al. directly observed etomidate and isoflurane reducing microtubule excitation diffusion length, and Emerson et al. photolabeled β-tubulin as an anesthetic target and showed stabilizers shifting behavioral concentration in tadpoles. It is held to provisional because the Kalra effect is a single unreplicated experiment with two agents and a modest ~13% effect, and the Emerson compound is a research anesthetic rather than a clinical agent. The strongest opposing consideration comes from inside the flagship experiment: picrotoxin, a convulsant, affected the same assay comparably, so what is being measured may be general perturbability of microtubule photophysics by small hydrophobic molecules rather than anything specific to anesthesia — and until a potency series with nonimmobilizer and hydrophobic non-anesthetic controls is run, the specificity this claim needs is absent.

Two partly independent experimental lines support the claim exactly as worded: etomidate and isoflurane reduce microtubule excitation diffusion length, and photolabeling from an anesthesia-mechanisms laboratory with no Orch OR commitment identifies β-tubulin as an anthracene anesthetic's target near the colchicine site with functional in vivo consequences. Held below "well_supported" because the Kalra result is a single unreplicated experiment with two agents and a modest (~13%) effect at or above clinical concentration, and the Emerson compound is a research anesthetic. The strongest opposing consideration is specificity, and it comes from inside the key experiment: picrotoxin, a convulsant, perturbed the same assay comparably, so what is demonstrated may be perturbability by small hydrophobic molecules rather than anything anesthetic-specific — though the claim as worded does not assert specificity.

Two partly independent lines support the claim as worded — ORCH-E002 and the photolabeling plus polymerization-inhibition results in ORCH-E009 — kept provisional by modest effect size, few agents, and the missing specificity panel implied by ORCH-E003. ORCH-E010 is modeling only and adds a prediction, not a confirmation.

Two partly independent lines support the claim as worded — ORCH-E002 and the photolabeling plus polymerization-inhibition results in ORCH-E009 — kept provisional by modest effect size, few agents, and the missing specificity panel implied by ORCH-E003. ORCH-E010 is modeling only and adds a prediction, not a confirmation.

Direct measurement shows anesthetics reducing exciton diffusion in microtubules (ORCH-E002), and photolabeling identifies tubulin as an on-pathway target (ORCH-E009). The strongest opposing consideration is that the convulsant picrotoxin suppressed the same optical assay (ORCH-E003), indicating the effect may measure general hydrophobic perturbability rather than specific anesthetic action.

Kalra et al. demonstrate that clinical anesthetics etomidate and isoflurane reduce an exciton-diffusion-derived microtubule optical observable (ORCH-C020/E002), and Emerson et al. identify β-tubulin as a photolabeled target for an anthracene anesthetic, with functional consequences for immobilization modulated by microtubule stabilizers (E009). These independent lines substantiate that anesthetics bind tubulin and alter microtubule electronic/optical behaviour. The strongest opposing consideration is the specificity problem: picrotoxin — a convulsant — also alters the Kalra assay comparably (E003), and no potency series with nonimmobilizers or hydrophobic controls has yet shown that the effect tracks anesthetic efficacy rather than generic perturbation.

Two independent experimental lines support the claim as worded, which does not require coherence, consciousness, or anesthetic specificity: Kalra et al. report etomidate and isoflurane reducing microtubule excitation diffusion, and Emerson et al. identified β-tubulin as the photolabeled target of an anthracene anesthetic with binding near the colchicine site and functional consequences in tadpoles. Limits that keep this provisional rather than well supported are a single unreplicated optical experiment with two agents, a research anesthetic rather than a clinical volatile in the photolabeling work, modest reported effect size, and unverified free aqueous concentration. Strongest opposing consideration comes from inside Kalra: picrotoxin reduced the same quenching behavior, so the assay may be measuring perturbability of microtubule photophysics by small hydrophobic molecules rather than an anesthesia-specific interaction.

Two independent experimental lines support the claim as worded: etomidate and isoflurane measurably reduce microtubule excitation diffusion (ORCH-E002), and β-tubulin was photolabeled as an anesthetic target with functional consequences in tadpoles (ORCH-E009), the latter from a laboratory with no Orch OR commitment. Held at provisional because the optical effect is a single unreplicated experiment with two agents and a modest ~13% effect size, and the photolabeled compound is a research anesthetic rather than a clinical volatile. The strongest opposing consideration is specificity, from inside the key experiment itself: picrotoxin — a convulsant — affected the same assay comparably (ORCH-E003, a detail relayed rather than directly verified), so the assay may measure general perturbability by small hydrophobic molecules rather than anything specific to anesthesia. Volatile anesthetics bind many brain proteins, so this claim removes an impossibility objection and little more.

Two partly independent lines support the claim as worded: β-tubulin photolabeling with functional consequences from an anesthesia-mechanisms laboratory with no Orch OR commitment (ORCH-E009), and a measured reduction in exciton diffusion by etomidate and isoflurane (ORCH-E002). The claim is deliberately modest — binding and altered optical behavior, nothing about coherence or consciousness — and the records reach that far. Limits: the Kalra effect is single-laboratory, unreplicated, roughly 13%, at 50 µM with free concentration unestablished, and Emerson's agent is a research anesthetic. The strongest opposing consideration is ORCH-E003: picrotoxin perturbed the same assay comparably, which does not falsify the observation but shows the effect may be generic to small hydrophobic molecules rather than to anesthetics.

Two partly independent lines support the claim as worded — ORCH-E002 and the photolabeling plus polymerization-inhibition results in ORCH-E009 — kept provisional by modest effect size, few agents, and the missing specificity panel implied by ORCH-E003. ORCH-E010 is modeling only and supplies a prediction, not a confirmation.

Two partly independent lines support the claim as worded — ORCH-E002 and the photolabeling plus polymerization-inhibition results in ORCH-E009 — kept provisional by modest effect size, few agents, and the missing specificity panel implied by ORCH-E003. ORCH-E010 is modeling only and adds a prediction, not a confirmation.

Kalra 2023 demonstrates exciton diffusion reduction by anesthetics, and Emerson 2013 shows direct tubulin binding for an anthracene anesthetic. The strongest objection is the profound lack of specificity, as the convulsant picrotoxin also suppresses the same photophysical assay.

Kalra et al. directly show that clinical anesthetics (etomidate, isoflurane) reduce exciton diffusion length in microtubules, and Emerson et al. identify β‑tubulin as a photolabeled target of an anthracene anesthetic with functional in vivo consequences in tadpoles. These independent lines support the assertion that anesthetics bind tubulin and alter microtubule optical/electronic behavior. The strongest opposing consideration is the lack of specificity: Kalra’s own data indicate that the convulsant picrotoxin produces a comparable effect, suggesting the assay may index general perturbation by hydrophobic ligands rather than an anesthesia-specific mechanism, and there is no potency series or in vivo linkage yet.

Two independent experimental lines support the statement as worded. Kalra et al. measured etomidate and isoflurane reducing microtubule excitation diffusion; Emerson et al. identified β-tubulin as the photolabeled target of an anthracene anesthetic and found microtubule stabilizers shifting the concentration needed to immobilize tadpoles. The claim does not itself require coherence, consciousness, or anesthetic specificity. The strongest opposing consideration comes from inside Kalra: picrotoxin, a convulsant, produced a comparable effect on the same assay, so what is shown is perturbability of microtubule photophysics by small hydrophobic molecules rather than an anesthesia-specific mechanism. Kalra is unreplicated and lists Hameroff and Penrose as co-authors; Emerson used a research anesthetic.

Two independent experimental lines support the claim as worded: Kalra et al. measured etomidate and isoflurane reducing microtubule excitation diffusion (ORCH-E002), and Emerson et al. — an anesthesia laboratory with no Orch OR commitment — identified β-tubulin as the photolabeled target of an anthracene anesthetic with functional consequences in vivo (ORCH-E009). The provisional grade reflects a single unreplicated photophysics experiment with two agents, a research rather than clinical anesthetic in the binding work, and a modest ~13% effect size. The strongest opposing consideration is specificity, raised by the flagship experiment itself: picrotoxin, a convulsant, reduced the same assay comparably (ORCH-E003), so what is demonstrated may be general perturbability of microtubule photophysics by small hydrophobic molecules rather than anything specific to anesthesia — a distinction only an unrun potency series can settle.

Two partly independent lines support the claim as worded: Emerson et al. photolabeled β-tubulin near the colchicine site with functional consequences in vivo (ORCH-E009), and Kalra et al. measured etomidate and isoflurane shortening exciton diffusion (ORCH-E002). Both have real limits — the Emerson anesthetic is a research compound with an immobility endpoint, and the Kalra effect is a single unreplicated ~13% shift from a paper co-authored by the theory's principals, with the specific reduced values unverified in this ledger. The strongest opposing consideration is the picrotoxin result inside that same paper (ORCH-E003): a convulsant moving the assay comparably means the observation is currently consistent with general perturbability of microtubule photophysics by small hydrophobic molecules.

Two partly independent lines support the claim as worded — ORCH-E002, and the photolabeling plus polymerization-inhibition results in ORCH-E009 — kept provisional by modest effect size, few agents, and the missing specificity panel implied by ORCH-E003. ORCH-E010 is modeling only and supplies a prediction, not a confirmation.

Two partly independent lines support the claim as worded — ORCH-E002 and the photolabeling plus polymerization-inhibition results in ORCH-E009 — kept provisional by modest effect size, few agents, and the missing specificity panel implied by ORCH-E003. ORCH-E010 is modeling only and supplies a prediction, not a confirmation.

Evidence-only: two independent experimental lines support this as worded. Kalra et al. measured etomidate and isoflurane reducing microtubule excitation diffusion length (6.6 nm to about 5.6 and 5.8 nm), which is a direct observation of anesthetics altering microtubule optical behavior. Emerson et al. independently identified β-tubulin as the photolabeled target of an anthracene anesthetic, mapped binding near the colchicine site, and showed microtubule stabilizers shift the concentration needed for behavioral effect. Proteomic photolabeling work also places tubulin among many anesthetic-binding brain proteins. The limits on "provisionally": the Kalra effect is a single unreplicated experiment with two agents, the Emerson compound is a research anesthetic rather than a clinical volatile, and the effect size in the Kalra assay is modest — around a 13% reduction in diffusion length.

Two convergent lines support it. ORCH-E009 is causal and comes from an anesthesia laboratory with no theoretical stake: β-tubulin photolabelled by an anthracene anesthetic, binding localized near the colchicine site, polymerization inhibited, and stabilizers raising the immobilizing concentration in tadpoles. ORCH-E002 shows two clinical anesthetics reducing microtubule exciton diffusion. Against that, ORCH-E010 is computational rather than experimental, ORCH-E084 through ORCH-E086 are a commentary's restatement of that computation rather than new data, and the specificity problem at ORCH-E003 applies directly: a convulsant affected the same assay comparably. So anesthetics binding tubulin and altering microtubule optics is provisionally established; that the alteration has anything to do with unconsciousness is a separate claim and is not.

Photolabeling with 1-aminoanthracene demonstrates direct anesthetic binding to β-tubulin near the colchicine site, and spectroscopic assays show that clinical anesthetics like etomidate and isoflurane shorten exciton diffusion in polymerized microtubules. These findings confirm direct binding and physical perturbation of tubulin's optical properties. The strongest opposing consideration is that picrotoxin, a non-anesthetic convulsant, causes an equivalent optical perturbation, suggesting a generic hydrophobic interaction rather than an anesthetic-specific mechanism.

Emerson et al. provide independent (non-Orch-OR) photolabeling evidence that anesthetics bind β-tubulin with functional consequences, and Kalra et al. directly show etomidate and isoflurane altering microtubule electronic behavior. The claim as worded survives its own study's picrotoxin control problem, since it says anesthetics do this rather than that only anesthetics do. Holding short of well_supported because Kalra is unreplicated, proponent-co-authored, uses two agents at or above clinical concentration, and the specific values were not independently verified against the paper body.

ORCH-E009 identifies β-tubulin as a direct target of a research anesthetic with effects on polymerization, while ORCH-E002 reports that etomidate and isoflurane alter microtubule excitation diffusion. Together they support binding and altered electronic or optical behavior, though not necessarily for every anesthetic in the same assay. The strongest opposing consideration is that picrotoxin produced a comparable optical effect, undermining anesthesia specificity rather than the underlying perturbation.

Emerson et al. photolabeled β-tubulin with a research anesthetic and showed functional polymerization and in vivo sensitivity consequences; Kalra et al. show clinical anesthetics reduce MT exciton diffusion. Strongest opposing consideration is limited agent coverage, uncertain free aqueous concentration, and the picrotoxin specificity failure on the same optical assay, which qualifies mechanism-to-anesthesia inference without erasing binding and optical alteration as stated.

ORCH-E009, from an independent laboratory, finds an anesthetic photolabelling β-tubulin and stabilizers raising the immobilizing dose. ORCH-E002 shows etomidate and isoflurane shortening exciton diffusion. ORCH-E003 undermines the specificity of the effect, not the binding or the optical change itself. ORCH-E010 and ORCH-E084 to ORCH-E086 are modelling and commentary. The claim is modest and the records fit it, but they rest on few agents.